Final results of the U-ACHIEVE Maintenance trial demonstrated superiority of upadacitinib over placebo in disease control of ulcerative colitis (UC), along with a favourable safety analysis. The primary and key secondary endpoints that comprised clinical, histological, and patient-reported outcomes were met.
Moderate-to-severe UC induction and maintenance therapy with the selective, JAK1-inhibiting, small molecule upadacitinib has been approved by the US FDA and as of recently also in Europe. Top abstract prize awardee Prof. Séverine Vermeire (University Hospital Leuven, Belgium) presented the final results from the U-ACHIEVE Maintenance study (NCT02819635) . Included were 681 patients between 16 and 75 years of age with moderately to severely active UC who had responded to a 45 mg upadacitinib induction therapy within the 2 identical trials U-ACCOMPLISH (NCT03653026) and U-ACHIEVE Induction (NCT02819635). For U-ACHIEVE Maintenance, these responders were re-randomised to 3 study arms: placebo, upadacitinib 15 mg, or upadacitinib 30 mg. Clinical remission in the adapted Mayo score, including rectal bleeding, stool frequency, and endoscopic results, was the primary endpoint. Among the secondary endpoints were maintenance of response, steroid-free remission, and patient-reported outcomes.
The mean age at baseline ranged from 41.7 to 43.0 years, 35.1% to 44.8% were women, and disease duration was around 8 years. Prior treatment with at least 1 biologic agent was observed in 45.9% to 48.0% of participants.
As previously published, the primary analysis of the study that comprised the first 451 participants showed significant superiority of both 15 and 30 mg upadacitinib dosages over placebo . These results were reinforced by the final analysis of all participants: 40.4% on 15 mg and 53.6% on 30 mg of upadacitinib reached clinical remission versus 10.8% on placebo (P<0.001 for both comparisons) . Positive secondary endpoints for the 15 mg and the 30 mg regimens of upadacitinib included maintenance of clinical response (65.6% and 77.5% vs 21.5%; both P<0.001) and corticosteroid-free clinical remission (52.3% and 64.6% vs 18.8%; both P<0.001). Furthermore, upadacitinib achieved significant better results for endoscopic improvement and maintenance, endoscopic remission, and mucosal improvement and healing (P<0.001 for both dosages and all comparisons with placebo). Prof. Vermeire especially highlighted the significant reductions in bowel urgency in 53.8% (15 mg) and 66.9% (30 mg) of the participants on the study drug compared with 18.4% on placebo (both P<0.001).
“Both of the doses were well tolerated – we did not observe any new safety signals compared with the smaller primary analysis or other non-UC indications,” Prof. Vermeire summarised the safety assessment. This final analysis supports the favourable benefit-risk profile of upadacitinib as a maintenance treatment in patients with moderately to severely active UC.
- Vermeire S. Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active ulcerative colitis: final results from the phase 3 U-ACHIEVE Maintenance study. OP001, UEG Week 2022, 8–11 October, Vienna, Austria.
- Danese S, et al. Lancet. 2022;399(10341):2113–2128.
Copyright ©2022 Medicom Medical Publishers
« Start low with brepocitinib and ritlecitinib in UC Next Article
Upadacitinib for CD: remarkable efficacy in induction therapy »
Table of Contents: UEGW 2022
Letter from the Editor
UEGW 2022 Highlights Podcast
IBD in 2022
Fast recapture of response with ozanimod after withdrawal in UC
Ozanimod treatment prompted substantial response after failure of response to induction
Etrasimod shows advantage over placebo in UC
Etrasimod reduces adaptive immune cells in the periphery in UC
Favourable maintenance rates for risankizumab also in delayed responders with CD
IL-23 inhibition reduces inflammatory biomarkers in pre-treated UC
Maintained symptom control with mirikizumab in UC
Mirikizumab successfully resolves active histologic inflammation in UC
Upadacitinib for CD: remarkable efficacy in induction therapy
Sustained maintenance results with upadacitinib in UC
Start low with brepocitinib and ritlecitinib in UC
Another chance for TYK2 inhibition in UC
Small molecule obefazimod shows promise in UC
Pivotal results of etrolizumab for CD partly disappointing
Better results for vedolizumab in early CD
Some patients with limited CD may benefit from an early surgical intervention
Dose-interval of adalimumab might be prolonged in CD patients in stable remission
What Is Hot in Upper GI Disorders?
Less ulcer bleeds early after H. pylori eradication in aspirin users
Dupilumab effective in paediatric patients with eosinophilic oesophagitis
Neoplasia in Barrett’s oesophagus: the earlier the intervention, the better the long-term outcome
Hepatology in 2022
Favourable pancreatitis outcomes with procalcitonin-based algorithm to guide antibiotic use
Portal hypertension is associated with poor prognosis in cirrhotic patients
Chances of transplant-free survival in PSC enhanced by colectomy with ileostomy
SARS-CoV-2: Booster doses of key importance for cirrhotic patients
What Is New in Pancreatic Cancer and Pancreatitis?
Fewer long-term interventions after delayed drainage in necrotising pancreatitis
Detection of Europe´s deadliest cancer: much room for improvement
Colorectal Carcinoma: Improving Diagnosis and Therapy
Immunotherapy response may be modulated by microbiome
Computer-aided colonoscopies improved adenoma detection rates
Screening-detected colorectal cancers may have superior surgical outcomes